Cambridge Medical Technologies (CMT) is pioneering a transformative leap in combat casualty and critical care medicine with its advanced biosensor platform. Originally founded on research funded by DARPA, the Army Research Office (ARO), and Walter Reed Army Institute of Research, CMT’s mission has been clear from the start: develop non-invasive, real-time monitoring of blood chemistry for soldiers in the field. Their breakthrough technology samples subcutaneous interstitial fluid (ISF) painlessly and analyzes it outside the body for key biomarkers—starting with glucose and lactate, and now expanding to include blood pH. This innovation is especially critical in military medicine, where early detection of hemorrhagic shock, sepsis, and metabolic failure can mean the difference between life and death. Traditional vital signs like heart rate and blood pressure often fail to reveal the severity of internal injuries or compensated shock. CMT’s biosensor platform fills this gap by continuously tracking biochemical indicators that reflect tissue perfusion (lactate), acid-base status (pH/base deficit), and stress response (glucose). These metrics are widely recognized in both civilian and military clinical guidelines as essential for guiding resuscitation and predicting outcomes. Unlike conventional blood tests that require invasive sampling and lab processing, CMT’s devices—such as the LabPatch and LabClasp—use a proprietary method to extract ISF through the skin without needles. Within seconds, they deliver accurate readings of lactate and glucose, with pH integration underway. This allows medics and clinicians to monitor trends in real time, enabling faster, more informed decisions during trauma care, sepsis management, and evacuation triage. For combat medics operating in austere environments, this technology is a game-changer. A wearable patch could continuously stream vital biochemical data from a wounded soldier to a handheld device, alerting caregivers to rising lactate or falling pH before traditional signs deteriorate. In emergency departments and ICUs, the same platform could reduce reliance on repeated blood draws, improve response times, and enhance patient outcomes. CMT’s work aligns directly with the goals of the Department of Defense’s Advanced Medical Monitor (AMM) initiative under the Medical Technology Enterprise Consortium (MTEC). As future combat operations are expected to produce mass casualties and strain medical resources, integrating biochemical monitoring into standard vital sign systems is no longer optional—it’s urgent. CMT’s technology offers a scalable, field-ready solution that brings ICU-level insight to the point of injury. In summary, CMT is redefining how we monitor and manage shock and sepsis in both military and civilian care. By combining non-invasive ISF sampling with rapid, multi-analyte analysis, their platform empowers caregivers with the data they need—when and where they need it most. COMPANY BACKGROUND: EXECUTIVES: Dr. John Currie, Inventor & Chief Science Officer, Jack Jachmann, CEO, ¤ James Cooke, CFO. FUNDING: $30M in investment. GRANTS: 3 SBIR awards totaling $2M. EXPERIENCE: 8 years of operation. INTELLECTUAL PROPERTY: 14 US and international patents. TEAM: 21 employees. LOCATIONS: Maryland & California (US), United Kingdom, Japan. MANUFACTURING: 2 contract chip manufacturers (US and Japan). CLINICAL TRIALS: 3 hospital sites in Massachusetts, 1 in Minnesota, 1 in Colorado. FOCUS AREAS: Emergency Medicine, Diabetes, Alcoholism & Addiction. MARKET: We are one year away from launching our monitor product, which will initially support four analytes, with additional planned analytic capabilities employing the same platform.